Detalhe da pesquisa
1.
Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis.
Eur J Haematol
; 112(6): 900-909, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38350661
2.
Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis.
Eur J Haematol
; 111(4): 536-543, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37401100
3.
A cross-sectional study of patient-reported outcomes and symptom burden using PROMIS and PRO-CTCAE measures in light chain amyloidosis.
Qual Life Res
; 32(6): 1807-1817, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36738402
4.
Development of a conceptual model of patient-reported outcomes in light chain amyloidosis: a qualitative study.
Qual Life Res
; 31(4): 1083-1092, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-34255276
5.
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis.
Clinicoecon Outcomes Res
; 15: 673-680, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37719133
6.
Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates.
Clin Med Insights Cardiol
; 15: 11795468211015230, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34104028
7.
Light Chain (AL) Amyloidosis: The Journey to Diagnosis.
Patient
; 11(2): 207-216, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28808991